Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis

Emma J. Schuster, Nurmaa K. Dashzeveg, Yuzhi Jia, Golam Kibria, Tong Zhang, Andrew R. Hoffman, Youbin Zhang, Chunlei Zheng, Erika K. Ramos, Rokana Taftaf, Lamiaa El- Shennawy, David Scholten, Reta Birhanu Kitata, Valery Adorno-Cruz, Carolina Reduzzi, Sabina Spahija, Rong Xu, Kalliopi P. Siziopikou, Leonidas C. Platanias, Ami N. Shah, William J. Gradishar, Massimo Cristofanilli, Chia‐Feng Tsai, Tujin Shi, Huiping LiubioRxiv 2023 · DOI

TL;DR

This study identifies Plexin-B2 (PB2) as a key driver of circulating tumor cell (CTC) clustering, a critical step in breast cancer metastasis. By combining computational ranking with experimental validation, the researchers found that PB2 promotes both tumor-cell-only (homotypic) and tumor-cell-immune-cell (heterotypic) clusters, ultimately enhancing lung metastasis. This work highlights PB2 as a promising therapeutic target for preventing cancer spread.

What Problem Does This Paper Address?

Metastasis is the primary cause of cancer-related deaths, yet predicting and preventing it remains a significant challenge. Circulating tumor cells (CTCs) are known to be precursors to metastasis, and importantly, CTCs that form multicellular clusters are far more likely to establish secondary tumors than single CTCs. However, the molecular mechanisms that drive the formation of these crucial CTC clusters, both those composed solely of tumor cells (homotypic) and those involving immune cells (heterotypic), are not well understood. This lack of understanding limits the development of effective strategies to prevent metastasis.

Methods

The researchers employed a multi-pronged approach:

  • Computational Ranking: They used systems biology and mass spectrometry (MS)-based global proteomic data to computationally rank cell adhesion molecules based on their abundance in breast tumors, TNBC cells, and extracellular vesicles (EVs). This helped identify potential candidates involved in CTC clustering.
  • Experimental Validation: Promising candidates were then experimentally tested. This included:
  • Cell Culture Assays: Using various breast cancer cell lines (including triple-negative breast cancer - TNBC), they performed clustering assays to observe the formation of homotypic and heterotypic clusters.
  • Gene Knockdown (KD) and Knockout (KO): They used siRNA (for KD) and CRISPR-Cas9 (for KO) to reduce or eliminate PB2 expression and observed the impact on cell clustering and other cellular processes.
  • Overexpression Studies: They overexpressed full-length PB2 and various mutant forms in PB2-deficient cells to pinpoint the functional domains responsible for clustering.
  • Co-immunoprecipitation: This technique was used to confirm direct interactions between PB2 and its potential ligands (Sema4C and Sema4A).
  • Proteomic Analysis: Global mass spectrometry was used to identify downstream effectors of the PB2 pathway.
  • In Vivo Metastasis Models: Mouse models were used to assess the role of PB2 in spontaneous lung metastasis and tail vein injection models to evaluate the impact of pre-formed clusters on metastasis.
  • Flow Cytometry and Imaging: These techniques were used for cell analysis, quantification, and visualization of CTCs, clusters, and protein expression.

Datasets

The study utilized several datasets:

  • Proteomics Datasets:
    • 122 treatment-naïve primary breast patient samples.
  • MDA-MB-231 triple-negative breast cancer (TNBC) cell lines.
  • Human breast tumor tissue voxels and adjacent normal mammary tissue voxels.
  • Small extracellular vesicles (EVs) secreted by breast cancer cell lines (MCF7, SKBR3, BT4T4, and MDA-MB-231) and normal immortalized epithelial cells (MCF10A and MCF12A).
  • Publicly Available Databases:
    • Molecular Signature Database for Gene Ontology Biological Processes.
  • Human Protein Atlas for single-cell RNA sequencing data.
  • KMPlotter for survival analysis.

No new benchmarks were introduced; rather, existing datasets were integrated and analyzed using computational ranking and experimental validation.

Key Insights and Ideas

  • PB2 as a Master Regulator of CTC Clustering: The study convincingly demonstrates that PB2 is not just correlated with, but actively drives the formation of both homotypic and heterotypic CTC clusters. This is a significant finding because it identifies a specific molecular target that can be manipulated to disrupt a key step in metastasis.
  • Hijacking the Sema/Plexin Axis: The research reveals how tumor cells leverage the PB2/Sema signaling pathway. Tumor cells use PB2 to interact with Sema4C on other tumor cells (homotypic clustering) and with Sema4A on monocytes (heterotypic clustering). This suggests a sophisticated mechanism where cancer cells exploit host immune cells to their advantage.
  • PB2's Role in Stemness and Proliferation: Beyond just clustering, PB2 appears to influence cancer stemness and potentially proliferation, as indicated by mammosphere formation assays. This suggests PB2 might contribute to the more aggressive and self-renewing properties of metastatic cells.
  • Therapeutic Potential: The identification of PB2 and its interaction partners (Sema4C/4A) as critical for metastasis opens up new avenues for targeted therapies, particularly for aggressive subtypes like TNBC, which often lack effective treatment options.

Key Results

  • PB2 is a Top Candidate: Computational ranking identified PB2 as a top candidate among adhesion molecules associated with poor prognosis in breast cancer.
  • PB2 Expression Correlates with Poor Prognosis: High PB2 expression in primary tumors was linked to unfavorable distant metastasis-free survival.
  • PB2 Enriched in CTC Clusters: PB2 expression was significantly higher in CTC clusters (both homotypic and heterotypic) compared to single CTCs.
  • PB2 KD/KO Inhibits Clustering: Knocking down or knocking out PB2 significantly reduced homotypic tumor cell clustering in multiple breast cancer cell lines.
  • PB2 Promotes Lung Metastasis: In vivo studies showed that PB2 knockdown dramatically reduced lung metastasis in mice.
  • Sema4C and Sema4A are Key Interactors: PB2 directly interacts with Sema4C on tumor cells and Sema4A on monocytes, mediating homotypic and heterotypic clustering, respectively.
  • Downstream Effectors Identified: Proteomic analysis revealed novel downstream effectors of the PB2 pathway, including MCM7, which also plays a role in cell clustering.

Limitations and Future Work

  • Context-Dependent Ligand Interactions: The authors note that the function of PB2 can be context-dependent, largely influenced by the specific ligands it interacts with and the microenvironmental conditions. While Sema4C and Sema4A were identified as key players in breast cancer, other known PB2 ligands might be involved in different cancer types or metastatic sites.
  • Further Investigation of Immune Cell Interactions: While monocytes were studied, the role of other immune cell types (e.g., neutrophils, MDMCs) in heterotypic CTC clusters warrants further investigation.
  • Therapeutic Development: The study identifies PB2 and its ligands as potential therapeutic targets. Future work will likely focus on developing drugs that block PB2 signaling or its interactions with Sema4C and Sema4A, particularly for TNBC.
  • Understanding Intravasation: The authors suggest that PB2's role in tumor-myeloid interactions might also promote intravasation (entry into the bloodstream), which could be a subject for future research.

Summary updated

Abstract

Metastasis is the cause of over 90% of all deaths associated with breast cancer, yet the strategies to predict cancer spreading based on primary tumor profiles and therefore prevent metastasis are egregiously limited. As rare precursor cells to metastasis, circulating tumor cells (CTCs) in multicellular clusters in the blood are 20-50 times more likely to produce viable metastasis than single CTCs. However, the molecular mechanisms underlying various CTC clusters, such as homotypic tumor cell clusters and heterotypic tumor-immune cell clusters, are yet to be fully elucidated. Combining machine learning-assisted computational ranking with experimental demonstration to assess cell adhesion candidates, we identified a transmembrane protein Plexin- B2 (PB2) as a new therapeutic target that drives the formation of both homotypic and heterotypic CTC clusters. High PB2 expression in human primary tumors predicts an unfavorable distant metastasis-free survival and is enriched in CTC clusters compared to single CTCs in advanced breast cancers. Loss of PB2 reduces formation of homotypic tumor cell clusters as well as heterotypic tumor-myeloid cell clusters in triple-negative breast cancer. Interactions between PB2 and its ligand Sema4C on tumor cells promote homotypic cluster formation, and PB2 binding with Sema4A on myeloid cells (monocytes) drives heterotypic CTC cluster formation, suggesting that metastasizing tumor cells hijack the PB2/Sema family axis to promote lung metastasis in breast cancer. Additionally, using a global proteomic analysis, we identified novel downstream effectors of the PB2 pathway associated with cancer stemness, cell cycling, and tumor cell clustering in breast cancer. Thus, PB2 is a novel therapeutic target for preventing new metastasis.
BibTeX
@misc{schuster2023computational,
  author = {Emma J. Schuster and Nurmaa K. Dashzeveg and Yuzhi Jia and Golam Kibria and Tong Zhang and Andrew R. Hoffman and Youbin Zhang and Chunlei Zheng and Erika K. Ramos and Rokana Taftaf and Lamiaa El- Shennawy and David Scholten and Reta Birhanu Kitata and Valery Adorno-Cruz and Carolina Reduzzi and Sabina Spahija and Rong Xu and Kalliopi P. Siziopikou and Leonidas C. Platanias and Ami N. Shah and William J. Gradishar and Massimo Cristofanilli and Chia‐Feng Tsai and Tujin Shi and Huiping Liu},
  title = {{Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis}},
  year = {2023},
  doi = {10.1101/2023.04.10.536233},
  howpublished = {bioRxiv},
}
Figure